Fig. 1. Response rates within the first 2 cycles of blinatumomab treatment, by subgroup.
a Complete remission (CR) rates in patients with ≥5% blasts at baseline. b Minimal residual disease (MRD) response rates.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.